Basics of cancer gene therapy

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2887-2890

  Runnebaum, Ingo B ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Adenovirus; Cytokine; Gene transfer; Retrovirus; Suicide gene; Tumor suppressor gene

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; PRODRUG; RIBOZYME; VIRUS VECTOR;

CANCER; CANCER CELL; CLONING VECTOR; CONFERENCE PAPER; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOGENICITY; ONCOGENE; PRIORITY JOURNAL; TRANSGENE; TUMOR SUPPRESSOR GENE;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0030817663     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Friedmann T and Roblin R: Gene therapy for human genetic disease? Science 175: 949-955, 1972.
2. Uckert W and Walther W: Retrovirus-mediated gene transfer in cancer therapy. Pharmacol Ther 63: 323-347, 1994.
3. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Ld S-P and Perricaudet M: Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434, 1991.
4. Engelhardt JF, Yang Y, Ld S-P, Allen ED, Kozarsky K, Perricaudet M, Yankaskas JR and Wilson JM: Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 4: 27-34, 1993.
5. Mastrangeli A, Danel C, Rosenfeld MA, L. S-P, Perricaudet M, Pavirani A, Lecocq JP and Crystal RG: Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J Clin Invest 91: 225-234, 1993.
6. Moss B and Flexner C: Vaccinia virus expression vectors. Annu Rev Immunol 5: 305-324, 1987.
7. Jolly D: Viral vector systems for gene therapy. Cancer Gene Ther 1: 51-64, 1994.
8. Fujiwara T, Grimm EA and Roth JA: Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 6: 96-105, 1994.
9. Lasic DD and Papahadjopoulos D: Liposomes revisited. Science 267: 1275-1276, 1995.
10. Miller AD, Miller DG and Garcia JV: Use of retroviral vectors for gene transfer and expression. Methods Enzymol 217: 581-599, 1993.
11. Runnebaum IB and Kreienberg R: p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: An expeditious in vitro protocol with implications towards gene therapy. Hybridoma 14: 153-157, 1995.
12. Burns JC, Friedmann T, Driever W, Burrascano M and Yee J-K: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90: 8033-8037, 1993.
13. Ostrove JM: safety testing programs for gene therapy viral vectors. Cancer Gene Ther 1: 125-131, 1994.
14. Tolstoshev P: Retroviral-mediated gene therapy - safety considerations and preclinical studies. Bone Marrow Transplant 1: 148-150, 1992.
15. Pardoll D: Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 4: 1124-1129, 1992.
16. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hirofumi H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
17. Horwitz MS: Adenoviridae and their replication. In: Virology (Field BN, Knipe DM, Chanock RM, Melnick JL, Hirsch MS, Monath TP and Roizman Bs, eds.). New York, Raven Press, 1990, pp. 1679-1729.
18. Friedmann T: Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer suppl 70: 1810-1817, 1992.
19. Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
20. Cheng J, Yee JK, Yeargin J, Friedmann T and Haas M: Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res 52: 222-226, 1992.
21. Runnebaum IB, Yee J-K, Kieback DG, Sukumar S and Friedmann T: Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles. Anticancer Res 14: 1137-1144, 1994.
22. Runnebaum IB, Wang S and Kreienberg R: Retrovirally mediated wild-type p53 restores S phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53. J Cell Biochem 59: 538-544, 1995.
23. Koizumi M, Kamiya H and Ohtsuka E: Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 117: 179-184, 1992.
24. Lu D, Chatterjee S, Brar D and Wong KJ: Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther 1: 267-277, 1994.
25. Poeschla E and Wong SF: Antiviral and anticancer ribozymes. Curr Opin Oncol 6: 601-606, 1994.
26. Freeman SM and Zwiebel JA: Gene therapy of cancer. Cancer Invest 11: 676-688, 1993.
27. Zhang WW, Fujiwara T, Grimm EA and Roth JA: Advances in cancer gene therapy. Adv Pharmacol 32: 289-341, 1995.
28. Pitts JD: Cancer gene therapy: a bystander effect using the gap junctional pathway. Mol Carcinog 11: 127-130, 1994.
29. Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO and Pastan I: Gene transfer of drug resistance genes. Implications for cancer therapy. Ann N Y Acad Sci 716: 126-138, 1994.
30. Hanania EG and Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1: 21-25, 1994.
31. Culver KW, Vickers TM, Lamsam JL, Walling HW and Seregina T: Gene therapy for solid tumors. Br Med Bull 51: 192-204, 1995.
32. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese AM and Anderson FW: Gene transfer into humans: Immunotherapy for patients with advanced melanoma, using tumor-infiltrating lymphoytes modified be retroviral gene transduction. N Engl J Med 323: 570-578, 1990.
33. Miller N and Vile R: Targeted vectors for gene therapy. Faseb J 9: 190-199, 1995.
34. Temin HM: Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther 1: 111-123, 1990.